Reuters: Global Markets: Merrimack cancer drug fails mid-stage study, shares fall

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Start taking a college level music theory class today. This beginner class is now accessible to aspiring musicians of all ages. Learn all of the basic concepts in an easy to follow manner. From our sponsors

Merrimack cancer drug fails mid-stage study, shares fall Oct 30th 2013, 12:24 Wed Oct 30, 2013 8:24am EDT (Reuters) - Merrimack Pharmaceuticals Inc said its cancer drug failed to meet the main goal of a mid-stage study in patients with advanced ovarian cancers. Shares of the company fell 10 percent in premarket trading. The drug, used in combination with an approved chemotherapy drug, paclitaxel, failed to improve survival without the cancer progressing in the overall patient population compared with paclitaxel alone. The combination also showed adverse events, including an increase in incidence of diarrhea and vomiting compared with paclitaxel alone. The study tested the drug, codenamed MM-121, in patients with metastatic or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer who were resistant to previous treatment or did not respond to it. Merrimack shares were down at $3.05 before the bell.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions